Current Status of Targeted Therapy in Metastatic Renal Cell Carcinoma

European Urology, Supplements

Volumn 6, Issue 10, 2007, Pages 665-671

  De Mulder, Pieter H M ^a   Patard, Jean Jaques ^b   Szczylik, Cezary ^c   Otto, Thomas ^d   Eisen, Tim ^e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c Military Institute   (Poland)

^d Klinik fur Urologie   (Germany)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Metastatic; Renal cell carcinoma; Targeted therapy

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CALGB 90206; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANEMIA; ANGIOGENESIS; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEUKOPENIA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; REVIEW; SKIN EXFOLIATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 34247221638     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.03.010     Document Type: Review

References (33)

1. Cohen H., and McGovern F. RenalCell carcinoma. N Engl J Med 353 (2005) 3477-3490
2. Available at URL: http://www.seer.cancer.gov. Accessed 2004.
3. Flanigan R.C., Mickisch G., Sylvester R., et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071-1076
4. Kavolius J.P., Mastorakos D.P., Pavlovich C., et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 16 (1998) 2261-2266
5. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163 (2000) 408-417
6. Stadler W.M., Huo D., George C., Yang X., et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 170 (2003) 1141-1145
7. Coppinn C, Porzsolt F, Awa A, et al. Cochrane Database Syst Rev 2005:CD001425.
8. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
9. Fossa S., Jones M., Johnson P., et al. Interferon-alpha and survival in renal cell cancer. Br J Urol 76 (1995) 286-290
10. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
11. Negrier S., Perol D., Ravaud A., et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 23 16 suppl pt I (2005) 4511
12. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721
13. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
14. Rini B.I., Weinberg V., Dunlap S., et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 106 (2006) 566-575
15. Donskov F., and von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 1997-2005
16. Gnarra J.R., Zhou S., Merrill M.J., et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Nat Acad Sci USA 93 (1996) 10589-10594
17. Turner K.J., Moore J.W., Jones A., et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62 (2002) 2957-2961
18. Wiesener M.S., Munchenhagen P.M., Berger I., et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 61 (2001) 5215-5222
19. Grabmaier K., de Weijert M.C.A., Verhaegh G.W., et al. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23 (2004) 5624-5631
20. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 (2001) 843-850
21. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
22. Bevacizimab plus IFN-alpha [press release].
23. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Onc 24 (2006) 16-24
24. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
25. Motzer R.J., Hutson T.E., Pharm D., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
26. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
27. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
28. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 (2004) 2336-2347
29. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
30. Smith J.W., Ko Y.J., Dutcher J., et al. Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma. J Clin Onc 22 14S (2004) 4513
31. Hudes G., Carducci M., Tomczak P., et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 24 2s (2006) (abstract no. LBA4)
32. Desai J., Yassa L., Marqusee E., et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 (2006) 660-664
33. Rini B.I., George D.J., Michaelson M.D., et al. Phase II study of Sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC). Ann Oncol 17 suppl 9 (2006) (abstract no. 4380)